Initiative of the U.S. Dept. of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment
Buprenorphine
On October 8, 2002, the Schedule III narcotic medications Subutex® (buprenorphine hydrochloride) and Suboxone® tablets (buprenorphine hydrochloride and naloxone hydrochloride) received FDA approval for the treatment of opioid addiction.
CSAT's Division of Pharmacologic Therapies
CSAT's Division of Pharmacologic Therapies (DPT) manages the day-to-day regulatory oversight activities necessary to implement new SAMHSA regulations (42 CFR Part 8) on the use of opioid agonist medications (methadone and LAAM) approved by the Food and Drug Administration (FDA) for addiction treatment.
Physician(s) Authorized to Prescribe Buprenorphine
The Physician Locator is an online resource designed to assist the States, medical and addiction treatment communities, potential patients, and/or their families in finding information on locating physicians who can prescribe buprenorphine (Suboxone® and Subutex®) for treatment of opioid addiction.
Methadone
Methadone is the most common medication for heroin addiction treatment and also the most controversial. This Web area provides information about the background, Methadone maintenance, references, and program directories for treatment.
The Recovery Month effort aims to promote the societal benefits of alcohol and drug use disorder treatment, laud the contributions of treatment providers and promote the message that recovery from alcohol and drug use disorders in all its forms is possible.
Materials and events posted on the National Alcohol and Drug Addiction Recovery Month (Recovery Month) Web site are solely the responsibility of the authors and do not necessarily represent the official views the U.S. Department of Health and Human Services, the Substance Abuse and Mental Health Services Administration or the Center for Substance Abuse Treatment.
